Review



cd47 ig like domain  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Addgene inc cd47 ig like domain
    Fig. 2 | Macrophages phagocytose CAR T cells in vitro and in patients. a, Phagocytosis of co-cultured CFSE+ CAR T cells by primary human macrophages by flow cytometry. Data are mean ± s.d. of n = 3 triplicate wells. Reproducible across n = 4 macrophage donors. b, The fold change in <t>CD47</t> and calreticulin expression on CAR T cells between days 25 and 16 of culture by flow cytometry. Data are mean ± s.d. of fold change of values (day 25/day 16) derived from n = 3 donors. MFI, mean fluorescence intensity. c, Microscopy images of Wright- Giemsa-stained histiocytes engulfing lymphocytes collected from the CSF of a patient with LBCL who was treated with CD19-28ζ CAR T cells. Representative
    Cd47 Ig Like Domain, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd47 ig like domain/product/Addgene inc
    Average 93 stars, based on 2 article reviews
    cd47 ig like domain - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Engineered CD47 protects T cells for enhanced antitumour immunity."

    Article Title: Engineered CD47 protects T cells for enhanced antitumour immunity.

    Journal: Nature

    doi: 10.1038/s41586-024-07443-8

    Fig. 2 | Macrophages phagocytose CAR T cells in vitro and in patients. a, Phagocytosis of co-cultured CFSE+ CAR T cells by primary human macrophages by flow cytometry. Data are mean ± s.d. of n = 3 triplicate wells. Reproducible across n = 4 macrophage donors. b, The fold change in CD47 and calreticulin expression on CAR T cells between days 25 and 16 of culture by flow cytometry. Data are mean ± s.d. of fold change of values (day 25/day 16) derived from n = 3 donors. MFI, mean fluorescence intensity. c, Microscopy images of Wright- Giemsa-stained histiocytes engulfing lymphocytes collected from the CSF of a patient with LBCL who was treated with CD19-28ζ CAR T cells. Representative
    Figure Legend Snippet: Fig. 2 | Macrophages phagocytose CAR T cells in vitro and in patients. a, Phagocytosis of co-cultured CFSE+ CAR T cells by primary human macrophages by flow cytometry. Data are mean ± s.d. of n = 3 triplicate wells. Reproducible across n = 4 macrophage donors. b, The fold change in CD47 and calreticulin expression on CAR T cells between days 25 and 16 of culture by flow cytometry. Data are mean ± s.d. of fold change of values (day 25/day 16) derived from n = 3 donors. MFI, mean fluorescence intensity. c, Microscopy images of Wright- Giemsa-stained histiocytes engulfing lymphocytes collected from the CSF of a patient with LBCL who was treated with CD19-28ζ CAR T cells. Representative

    Techniques Used: In Vitro, Cell Culture, Flow Cytometry, Expressing, Derivative Assay, Fluorescence, Microscopy, Staining

    Fig. 4 | An engineered variant of CD47 retains binding to SIRPα, but no longer binds to anti-CD47 antibodies. a, Consensus mutations identified in yeast sequenced after sorts 4, 5 and 6. Frequencies of identified mutations out of n = 13, 16 and 12 sequenced clones for sorts 4, 5 and 6, respectively. b, Normalized binding of B6H12, CV-1, human SIRPα and mouse SIRPα to yeast-displayed CD47 WT, CD47(A30P) and CD47(Q31P). c, Crystal structures of CD47 (red) binding to SIRPα (dark pink, left) and B6H12 (light blue, right); residues Ala30 (gold) and Gln31 (blue) are indicated by boxes. d, Normalized binding of human SIRPα, B6H12, TJC4 and Hu5F9 to yeast-displayed CD47 WT, CD47(A30P), CD47(Q31P), CD47(A30P/Q31A) and CD47(E29A). e, Normalized binding of B6H12, TJC4, human SIRPα and mouse SIRPα to full-length CD47 WT,
    Figure Legend Snippet: Fig. 4 | An engineered variant of CD47 retains binding to SIRPα, but no longer binds to anti-CD47 antibodies. a, Consensus mutations identified in yeast sequenced after sorts 4, 5 and 6. Frequencies of identified mutations out of n = 13, 16 and 12 sequenced clones for sorts 4, 5 and 6, respectively. b, Normalized binding of B6H12, CV-1, human SIRPα and mouse SIRPα to yeast-displayed CD47 WT, CD47(A30P) and CD47(Q31P). c, Crystal structures of CD47 (red) binding to SIRPα (dark pink, left) and B6H12 (light blue, right); residues Ala30 (gold) and Gln31 (blue) are indicated by boxes. d, Normalized binding of human SIRPα, B6H12, TJC4 and Hu5F9 to yeast-displayed CD47 WT, CD47(A30P), CD47(Q31P), CD47(A30P/Q31A) and CD47(E29A). e, Normalized binding of B6H12, TJC4, human SIRPα and mouse SIRPα to full-length CD47 WT,

    Techniques Used: Variant Assay, Binding Assay, Clone Assay



    Similar Products

    cd47 ig like domain  (Addgene inc)
    93
    Addgene inc cd47 ig like domain
    Fig. 2 | Macrophages phagocytose CAR T cells in vitro and in patients. a, Phagocytosis of co-cultured CFSE+ CAR T cells by primary human macrophages by flow cytometry. Data are mean ± s.d. of n = 3 triplicate wells. Reproducible across n = 4 macrophage donors. b, The fold change in <t>CD47</t> and calreticulin expression on CAR T cells between days 25 and 16 of culture by flow cytometry. Data are mean ± s.d. of fold change of values (day 25/day 16) derived from n = 3 donors. MFI, mean fluorescence intensity. c, Microscopy images of Wright- Giemsa-stained histiocytes engulfing lymphocytes collected from the CSF of a patient with LBCL who was treated with CD19-28ζ CAR T cells. Representative
    Cd47 Ig Like Domain, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd47 ig like domain/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    cd47 ig like domain - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 2 | Macrophages phagocytose CAR T cells in vitro and in patients. a, Phagocytosis of co-cultured CFSE+ CAR T cells by primary human macrophages by flow cytometry. Data are mean ± s.d. of n = 3 triplicate wells. Reproducible across n = 4 macrophage donors. b, The fold change in CD47 and calreticulin expression on CAR T cells between days 25 and 16 of culture by flow cytometry. Data are mean ± s.d. of fold change of values (day 25/day 16) derived from n = 3 donors. MFI, mean fluorescence intensity. c, Microscopy images of Wright- Giemsa-stained histiocytes engulfing lymphocytes collected from the CSF of a patient with LBCL who was treated with CD19-28ζ CAR T cells. Representative

    Journal: Nature

    Article Title: Engineered CD47 protects T cells for enhanced antitumour immunity.

    doi: 10.1038/s41586-024-07443-8

    Figure Lengend Snippet: Fig. 2 | Macrophages phagocytose CAR T cells in vitro and in patients. a, Phagocytosis of co-cultured CFSE+ CAR T cells by primary human macrophages by flow cytometry. Data are mean ± s.d. of n = 3 triplicate wells. Reproducible across n = 4 macrophage donors. b, The fold change in CD47 and calreticulin expression on CAR T cells between days 25 and 16 of culture by flow cytometry. Data are mean ± s.d. of fold change of values (day 25/day 16) derived from n = 3 donors. MFI, mean fluorescence intensity. c, Microscopy images of Wright- Giemsa-stained histiocytes engulfing lymphocytes collected from the CSF of a patient with LBCL who was treated with CD19-28ζ CAR T cells. Representative

    Article Snippet: Yeast surface display vectors A DNA sequence encoding the CD47 Ig-like domain (Gln19–Ser135) was cloned into the pCTCON2 yeast-surface display vector (Addgene) using the NheI and BamHI sites.

    Techniques: In Vitro, Cell Culture, Flow Cytometry, Expressing, Derivative Assay, Fluorescence, Microscopy, Staining

    Fig. 4 | An engineered variant of CD47 retains binding to SIRPα, but no longer binds to anti-CD47 antibodies. a, Consensus mutations identified in yeast sequenced after sorts 4, 5 and 6. Frequencies of identified mutations out of n = 13, 16 and 12 sequenced clones for sorts 4, 5 and 6, respectively. b, Normalized binding of B6H12, CV-1, human SIRPα and mouse SIRPα to yeast-displayed CD47 WT, CD47(A30P) and CD47(Q31P). c, Crystal structures of CD47 (red) binding to SIRPα (dark pink, left) and B6H12 (light blue, right); residues Ala30 (gold) and Gln31 (blue) are indicated by boxes. d, Normalized binding of human SIRPα, B6H12, TJC4 and Hu5F9 to yeast-displayed CD47 WT, CD47(A30P), CD47(Q31P), CD47(A30P/Q31A) and CD47(E29A). e, Normalized binding of B6H12, TJC4, human SIRPα and mouse SIRPα to full-length CD47 WT,

    Journal: Nature

    Article Title: Engineered CD47 protects T cells for enhanced antitumour immunity.

    doi: 10.1038/s41586-024-07443-8

    Figure Lengend Snippet: Fig. 4 | An engineered variant of CD47 retains binding to SIRPα, but no longer binds to anti-CD47 antibodies. a, Consensus mutations identified in yeast sequenced after sorts 4, 5 and 6. Frequencies of identified mutations out of n = 13, 16 and 12 sequenced clones for sorts 4, 5 and 6, respectively. b, Normalized binding of B6H12, CV-1, human SIRPα and mouse SIRPα to yeast-displayed CD47 WT, CD47(A30P) and CD47(Q31P). c, Crystal structures of CD47 (red) binding to SIRPα (dark pink, left) and B6H12 (light blue, right); residues Ala30 (gold) and Gln31 (blue) are indicated by boxes. d, Normalized binding of human SIRPα, B6H12, TJC4 and Hu5F9 to yeast-displayed CD47 WT, CD47(A30P), CD47(Q31P), CD47(A30P/Q31A) and CD47(E29A). e, Normalized binding of B6H12, TJC4, human SIRPα and mouse SIRPα to full-length CD47 WT,

    Article Snippet: Yeast surface display vectors A DNA sequence encoding the CD47 Ig-like domain (Gln19–Ser135) was cloned into the pCTCON2 yeast-surface display vector (Addgene) using the NheI and BamHI sites.

    Techniques: Variant Assay, Binding Assay, Clone Assay